Mid-Atlantic Bio

The Mid-Atlantic Bio conference program combines networking events and education sessions to offer attendees an experience where they can maximize opportunities to meet the right people in the field while learning about the latest advances that will impact their businesses. 

Schedule At A Glance

1:00pm – 1:30pm – Registration
1:30pm – 1:45pm – Welcome
1:45pm – 2:45pm – Panel Session
2:45pm – 3:00pm – Break
3:00pm – 4:00pm – Panel Session
4:00pm – 4:15pm – Break
4:15pm – 5:15pm – Panel Session
5:30pm – 7:30pm – Reception

Panel Details

1:45 – 2:45 p.m.
How deep genetic information is transforming biomedicine and biobusiness
Where is the latest science leading? How will trends in sequencing and its application in diagnostics and genetic diversity impact Maryland and Virginia bioscience and device companies? Join these experts as they discuss how deep sequencing is transforming research and new business opportunities.
Moderator:  Brian A. Pollok, Ph.D., President, ATCC
Panelists:
Andrea Ferreira-Gonzalez, Ph.D., Director Molecular Diagnostics Lab, Virginia Commonwealth University
Sara Nayeem, Principal, New Enterprise Associates
Karen Nelson, Ph.D., Director Rockville Maryland campus, J. Craig Venter Institute
Ken C. Carter, Ph.D., President and CEO, Noble Life Sciences

3:00 – 4:00 p.m.
The Regulatory Landscape in 2012: How will Washington affect the bioscience industry next year and beyond?
What goes on in Capitol Hill has a major impact on what we do at the lab bench. In this very high level session, senior officials from the White House, NIH and BIO discuss the current state of our industry -  how the current legislative climate will impact access to capital and efforts by theAdministration to ensure life science innovation.
Moderator:  Sara Radcliffe, Executive Vice President Health, Biotechnology Industry Organization (BIO)
Panelists:
Michael Stebbins,Assistant Director, Biotechnology – Office of Science and Technology Policy, The White House
Francis Patrick  White, Associate Director for Legislative Policy and Analysis, National Institutes for Health

4:15 – 5:15 p.m.
Financing Drug Development in Today’s Environment: New Challenges and Opportunities
The third panel will address drug development challenges in today’s funding environment.  Biopharma entrepreneurs and investors will discuss changes in drug development costs in recent years, including shifts at the FDA, the emergence of “virtual models” to reduce cash burn, and the added complexity / promise of companion diagnostics and targeted therapies.  The panel will also cover current financing trends, such as changes in average capital into biotech over the life of the company, willingness of VCs to fund late-stage clinical trials, the current IPO market for pre-approval companies, big pharma interest in post-P2 products, and the opportunities presented by partnerships in Asia.
Moderator:  Amir Nashat, General Partner, Polaris Venture Partners
Panelists: 
Philippe Chambon, Managing Director and founder, New Leaf Venture Partners
Robert Gould, Ph.D., CEO, Epizyme Pharmaceuticals
Maxine Gowen, Ph.D., founding President and CEO, Trevena
John Kiernan IB Managing Director, Stifel Nicolaus Weisel